(CRMD) CorMedix - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US21900C3088

CRMD: Antimicrobial, Catheter, Lock, Solution

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for infectious and inflammatory diseases, with a focus on addressing unmet medical needs. The companys lead product candidate, DefenCath, is an antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in adult patients with renal failure. CRBSIs are a significant concern in healthcare, often leading to severe complications and increased mortality rates. DefenCath aims to reduce these risks by incorporating a broad-spectrum antimicrobial agent into a catheter lock solution, which is a critical component in the management of dialysis and other vascular access procedures.

CorMedix Inc. was originally incorporated in 2006 under the name Picton Holding Company, Inc., and underwent a name change to CorMedix, Inc. in January 2007. Headquartered in Berkeley Heights, New Jersey, the company has established itself as a player in the pharmaceutical industry, particularly in the development of anti-infective therapies. Its focus on innovative solutions for preventing and treating infections aligns with the growing demand for antimicrobial technologies in healthcare settings.

From a stock performance perspective, CRMD has shown notable volatility, with key support levels identified at 10.1, 7.0, 5.2, and 3.3. The stock is currently trading at 10.25, slightly below its 20-day simple moving average (SMA) of 10.41 but above its 50-day SMA of 10.19. The 200-day SMA stands at 7.81, indicating that the stock has been on an upward trajectory over the past year. The average trading volume over the last 20 days is approximately 750,213 shares, with an average true range (ATR) of 0.64, suggesting moderate volatility.

On the fundamental side, CorMedix Inc. has a market capitalization of $624.37 million, reflecting its position as a small-cap company in the pharmaceutical sector. The forward P/E ratio of 15.53 indicates investor expectations for future earnings growth, though the current P/E ratio is 0.00, likely due to the companys ongoing losses. The price-to-book (P/B) ratio of 10.44 and price-to-sales (P/S) ratio of 50.92 suggest that the market is valuing the companys future potential highly, despite its current financial performance. The return on equity (RoE) of -78.60% highlights the companys significant losses relative to shareholder equity, a common scenario for early-stage biopharmaceutical companies.

Looking ahead, the next three months are likely to be pivotal for CorMedix Inc. Based on the technical data, the stock may face resistance near the 10.41 level (20-day SMA) and could experience support at 10.1. If the stock breaks above the 20-day SMA, it may test higher resistance levels, potentially driven by positive news on DefenCaths regulatory progress or commercialization efforts. Conversely, a breakdown below the 7.0 support level could signal a broader correction, particularly if the company faces setbacks in its development pipeline or if market sentiment shifts.

Fundamentally, the companys ability to advance DefenCath through regulatory approvals and demonstrate commercial viability will be critical drivers of its performance. Given the high valuation multiples, any positive developments on the regulatory front could lead to a re-rating of the stock. However, the companys high P/S and P/B ratios also suggest that investors are pricing in significant future growth, which may not materialize if DefenCath fails to gain traction in the market. As such, the stock is likely to remain volatile, with its performance closely tied to catalysts such as clinical trial results, regulatory decisions, and commercialization updates.

Additional Sources for CRMD Stock

CRMD Stock Overview

Market Cap in USD 630m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2010-03-25

CRMD Stock Ratings

Growth 5y 48.2%
Fundamental -38.8%
Dividend 0.0%
Rel. Strength Industry 148
Analysts 4.25/5
Fair Price Momentum 9.74 USD
Fair Price DCF -

CRMD Dividends

No Dividends Paid

CRMD Growth Ratios

Growth Correlation 3m 36.1%
Growth Correlation 12m 81.1%
Growth Correlation 5y -6.7%
CAGR 5y 28.26%
CAGR/Max DD 5y 0.33
Sharpe Ratio 12m -0.05
Alpha 134.66
Beta 1.79
Volatility 73.56%
Current Volume 404.3k
Average Volume 20d 672.9k
What is the price of CRMD stocks?
As of March 15, 2025, the stock is trading at USD 10.47 with a total of 404,281 shares traded.
Over the past week, the price has changed by -2.24%, over one month by -0.10%, over three months by +25.99% and over the past year by +150.48%.
Is CorMedix a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, CorMedix (NASDAQ:CRMD) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.81 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRMD as of March 2025 is 9.74. This means that CRMD is currently overvalued and has a potential downside of -6.97%.
Is CRMD a buy, sell or hold?
CorMedix has received a consensus analysts rating of 4.25. Therefor, it is recommend to buy CRMD.
  • Strong Buy: 1
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for CRMD stock price target?
According to ValueRays Forecast Model, CRMD CorMedix will be worth about 11.2 in March 2026. The stock is currently trading at 10.47. This means that the stock has a potential upside of +6.59%.
Issuer Forecast Upside
Wallstreet Target Price 16.5 57.6%
Analysts Target Price 16.5 57.6%
ValueRay Target Price 11.2 6.6%